Counterfeit or Substandard? Assessing Price and Non-Price Signals of Drug Quality

Roger Bate, Ginger Zhe Jin, Aparna Mathur

NBER Working Paper No. 18073
Issued in May 2012
NBER Program(s):   IO

Pharmaceutical products can be of poor quality either because they contain zero correct active ingredient (referred to as "counterfeit") or because they contain a non-zero but incorrect amount of the right active ingredient (referred to as "substandard"). While both types of poor-quality drugs can be dangerous, they differ in health consequence, price, and potential policy remedies. Assessing basic quality of 1437 samples of Ciprofloxacin from 18 low-to-middle-income countries, we aim to understand how price and non-price signals can help distinguish counterfeits, substandard drugs, and passing drugs.

Following the Global Pharma Health Fund e.V. Minilab® protocol, we find 9.88% of samples have less than 80% of the correct active ingredient and 41.5% of these failures are counterfeits. Both product registration and chain affiliation of retailers are strong indicators of higher probability to pass in the Minilab test and higher retail price. Within quality failures, chain affiliation is more likely to indicate substandard while product registration with local government is more likely to indicate counterfeit. This suggests that registered products are more likely to be targeted by counterfeiters. Furthermore, substandard drugs are priced much lower than comparable generics in the same city but counterfeits offer almost no discount from the targeted genuine version. These findings are consistent with economic theory, and have important implications for both consumers and policy makers.

download in pdf format
   (463 K)

email paper

This paper is available as PDF (463 K) or via email.

This paper was revised on October 17, 2012

Machine-readable bibliographic record - MARC, RIS, BibTeX

Document Object Identifier (DOI): 10.3386/w18073

Roger Bate, Ginger Zhe Jin and Aparna Mathur# “Falsified or Substandard? Assessing Price and Non-Price Signals of Drug Quality” forthcoming the Journal of Economics & Management Strategy, also available as NBER working paper #18073.

Users who downloaded this paper also downloaded these:
Bate, Jin, and Mathur w16854 Does Price Reveal Poor-Quality Drugs? Evidence from 17 Countries
Bate, Jin, and Mathur w17955 In Whom We Trust: The Role of Certification Agencies in Online Drug Markets
Qian w17849 Brand Management and Strategies Against Counterfeits
Bate, Jin, Mathur, and Attaran w20469 Poor Quality Drugs and Global Trade: A Pilot Study
Qian w16785 Counterfeiters: Foes or Friends? How Do Counterfeits Affect Different Product Quality Tiers?
NBER Videos

National Bureau of Economic Research, 1050 Massachusetts Ave., Cambridge, MA 02138; 617-868-3900; email:

Contact Us